Trials / Completed
CompletedNCT01529203
Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess subjects' satisfaction linked to the pan facial management of rejuvenation with injections of Azzalure® and Restylane® fillers. This will be an open, multi-centre study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A (Azzalure) | Powder for solution for injection |
| DEVICE | Restylane ranges | Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh) |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-02-08
- Last updated
- 2021-02-18
- Results posted
- 2014-04-25
Locations
5 sites across 3 countries: France, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01529203. Inclusion in this directory is not an endorsement.